Cited by 278Receptor Mechanisms and SignalingEstrogen and related hormone effectsProstate Cancer Treatment and Research

Comparison of Crystal Structures of Human Androgen Receptor Ligand-Binding Domain Complexed with Various Agonists Reveals Molecular Determinants Responsible for Binding Affinity

Open access
Pereira de Jésus‐Tran, Karine, Côté, Pierre‐Luc, Cantin, Line, Blanchet, Jonathan, Labrie, Fernand, Breton, Rock·2006·Protein Science

Abstract

Androgens exert their effects by binding to the highly specific androgen receptor (AR). In addition to natural potent androgens, AR binds a variety of synthetic agonist or antagonist molecules with different affinities. To identify molecular determinants responsible for this selectivity, we have determined the crystal structure of the human androgen receptor ligand-binding domain (hARLBD) in complex with two natural androgens, testosterone (Testo) and dihydrotestosterone (DHT), and with an androgenic steroid used in sport doping, tetrahydrogestrinone (THG), at 1.64, 1.90, and 1.75 A resolution, respectively. Comparison of these structures first highlights the flexibility of several residues buried in the ligand-binding pocket that can accommodate a variety of ligand structures. As expected, the ligand structure itself (dimension, presence, and position of unsaturated bonds that influence the geometry of the steroidal nucleus or the electronic properties of the neighboring atoms, etc.) determines the number of interactions it can make with the hARLBD. Indeed, THG--which possesses the highest affinity--establishes more van der Waals contacts with the receptor than the other steroids, whereas the geometry of the atoms forming electrostatic interactions at both extremities of the steroid nucleus seems mainly responsible for the higher affinity measured experimentally for DHT over Testo. Moreover, estimation of the ligand-receptor interaction energy through modeling confirms that even minor modifications in ligand structure have a great impact on the strength of these interactions. Our crystallographic data combined with those obtained by modeling will be helpful in the design of novel molecules with stronger affinity for the AR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1110/ps.051905906

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Molecular docking used PDB entries 3OLL, 3UUD and 2AM9 for ERβ, ERα and AR, respectively, selected as ligand-bound crystal structures to allow ligand docking into the ligand-binding site.

    “In these experiments, the protein data bank (PDB) entries 3OLL, 3UUD and 2AM9 were used for ERβ, ERα and AR, respectively [84,85,86]. These crystal structures were specifically selected as they are in ligand-bound states and therefore their conformations would allow ligand docking into the ligand-binding site.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pereira de Jésus‐Tran, K., Côté, P., Cantin, L., Blanchet, J., Labrie, F., & Breton, R.
Affiliations
Centre hospitalier de l'Université Laval (CA)
Corresponding author
Breton, Rock
Venue
Protein Science
Publisher
Wiley
Published
2006-05
Volume
15
Issue
5
Pages
987-999
ISSN
  • 0961-8368 (ISSN-L)
  • 1469-896X
OpenAlex
W2052420006
Cited by
278
References
60
Citations by year
2026: 7 · 2025: 13 · 2024: 28 · 2023: 16 · 2022: 16 · 2021: 16 · 2020: 10 · 2019: 20 · 2018: 16 · 2017: 12 · 2016: 20 · 2015: 11 · 2014: 17 · 2013: 17 · 2012: 8
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • Protein Science (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Natural Sciences and Engineering Research Council of Canada
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Keywords
androgen receptor, ligand-binding domain, testosterone, dihydrotestosterone, binding affinity, ligand-receptor interactions, electrostatic interactions, van der Waals contacts, steroid structure, receptor-ligand complex structure
MeSH terms
Androgen Antagonists, Androgens, Binding Sites, Crystallization, Gestrinone, Humans, Hydrogen Bonding, Ligands, Protein Binding, Receptors, Androgen, Dihydrotestosterone, Testosterone, Molecular Structure, Protein Structure, Tertiary, Crystallography, X-Ray, Multiprotein Complexes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review